Document Type : Original Article


Synthesis and Molecular Simulation Laboratory, Chemistry Department, Pars Isotope Company, P.O. Box: 1437663181, Tehran, Iran


The main purpose of the present research article is the docking analysis of [11C]LY2795050 radiopharmaceutical with kappa (κ) and mu (µ) opioid receptors (KOR and MOR) and comparison of MOR-ligand and KOR-ligand complexes. In the first step, the title compound was optimized using B3LYP/6-31+G(d,p) basis set of theory at room temperature by Gaussian 03 software. Its reactivity and stability was done by frontier molecular orbitals (FMOs) theory. The molecular orbitals calculations indicate that this molecule prefers to react only with powerful nucleophile agents. The second step of this study is related to the docking analysis of the Ligand [11C]LY2795050 embedded in the active site of the kappa (κ) and mu (µ) opioid receptors. This work is done using Molegro Virtual Docker (MVD) software. The docking studies show that the possibility of the ligand-KOR complex formation is more than the ligand-MOR complex.

Graphical Abstract

Exploring molecular docking and electronic studies of [11C]LY2795050 as a novel antagonist tracer for positron emission tomography (PET) scan of the kappa (κ) and mu (µ) opioid receptors (KOR and MOR)


Main Subjects

[1]. Koehl A., Hu H., Maeda S., Zhang Y., Qu Q., Paggi J.M., Latorraca N.R., Hilger D., Dawson R., Matile H., Schertler G.F.X., Granier S., Weis W.I., Dror R.O., Manglik A., Skiniotis G., Kobilka B.K. Nature, 2018, 558:547
[2]. Naser P.V., Kuner R. Neuron, 2018, 99:1102
[3]. Chavkin C., Cohen J.H., Land B.B. Front. Pharmacol, 2019, 10: 88
[4]. Abraham A.D., Fontaine H.M., Song A.J., Andrews M.M., Baird M.A., Kieffer B.L., Land B.B., Chavkin C. Neuropsychopharmacology, 2018, 43: 362
[5]. Lutz P.E., Gross J.A., Dhir S.K., Maussion G., Yang J., Bramoulle A., Meaney M.J., Turecki G. Biol. Psychiatry, 2018, 84: 751
[6]. Wang D., Tawfik V.L., Corder G., Low S.A., Francois A., Basbaum A.I., Scherrer G. Neuron, 2018, 98: 90
[7]. Abraham A.D., Schattauer S.S., Reichard K.L., Cohen J.H., Fontaine H.M., Song A.J., Johnson S.D., Land B.B., Chavkin C. J. Neurosci. 2018, 38: 8031
[8]. Meral D., Provasi D., Prada-Gracia D., Moller J., Marino K., Lohse M.J., Filizola M. Scientific Reports, 2018, 8: 7705
[9]. Cheng J.X., Cheng T., Li W., Liu G., Zhu W., Tang Y. Acta Pharmacologica Sinica, 2018, 39: 154.
[10]. Pellissier L.P., Gandia J., Laboute T., Becker J.A.J., Merrer J.L. British J. Pharmacol. 2018, 175: 2750
[11]. Yang L., Brooks A., Makaravage K., Sanford M., Scott P., Shao X. J. Nucl. Med. 2018, 59: 1065
[12]. Vijay A., Cavallo D., Goldberg A., Nabulsi N., Najafzadeh S., Lin S., Lara-Jaime T., Huang Y., Krishnan-Sarin S., Morris E. J. Nucl. Med., 2018, 59: 550
[13]. Yang L., Brooks A., Makaravage K.J., Zhang H., Sanford M.S., Scott P.H., Shao X. ACS Med. Chem. Lett., 2018, 9: 1274
[14]. Nabati M. Chem. Method., 2018, 2: 223
[15]. Nabati M., Kermanian M., Mohammadnejad-Mehrabani H., Kafshboran H.R., Mehmannavaz M., Sarshar S. Chem. Method. 2018, 2: 128
[16]. Nabati M. Asian J. Green Chem., 2019, 3: 258
[17]. Nabati M. J. Phys. Theor. Chem. IAU Iran, 2017, 14: 283
[18]. Nabati M. Chem. Method. 2017, 1: 121
[19]. Nabati M. J. Phys. Theor. Chem. IAU Iran, 2017, 14: 49
[20]. Nabati M., Mahkam M., Atani Y.G. J. Phys. Theor. Chem. IAU Iran, 2016, 13: 35
[21]. Nabati M., Mahkam M. Org. Chem. Res., 2016,2: 70
[22]. Nabati M., Sabahnoo H., Lohrasbi E., Mazidi M. Chem. Method., 2019, 3: 383
[23]. Nabati M. Iran. Chem Commun., 2019, 7: 324
[24]. Nabati M., Sabahnoo H. J. Med. Chem. Sci., 2019, 2: 118
[25]. Nabati M., Mohammadnejad-Mehrabani H., Tavakkoli A., Mazidi M., Lohrasbi E., Gravand A., Sabahnoo H. Asian J. Green Chem. Accepted in 2019, in press